Background: Genetic alterations impacting on ubiquitously expressed proteins involved in
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Background
Neurons are highly specialised cells, reliant on precise spatial and temporal control of translation to maintain their unique anatomy and physiology. Local control of protein synthesis allows neurons to regulate axonal outgrowth and growth cone dynamics during development, and to control the complex cellular processes required for maintaining neuronal homeostasis throughout the life-span [1] . It is therefore not surprising that dysregulation of translation has been linked to the pathogenesis of several neurological diseases [2] [3] [4] [5] [6] [7] .
Genetic studies of familial and sporadic forms of motor neuron diseases have identified mutations in genes encoding RNA binding proteins (RBPs) or in their interactors as active contributors to disease pathogenesis [8] [9] [10] [11] . It remains unclear, however, why defects in ubiquitously expressed components of RNA metabolism lead to defects that are largely restricted to selected cell populations, and the extent to which changes in translation play a causative role in neurodegeneration in vivo remains to be fully determined.
Spinal muscular atrophy (SMA) is the most common genetic cause of infant mortality, with an incidence of around 1 in 6,000-10,000 live births [12, 13] . SMA is primarily associated with a loss of lower motor neurons from the spinal cord, leading to muscle atrophy and, eventually, paralysis. In the most common and severe cases of SMA (type I), onset typically occurs around 6 months of age and mortality before two years [13] . SMA is caused by low levels of full-length survival of motor neuron protein (SMN). Humans have two copies of the gene encoding SMN; SMN1 and SMN2. Approximately 95% of SMA cases are caused by homozygous deletion of SMN1, with a smaller number caused by discrete mutations within the gene. SMN1 and SMN2 are 99.9% identical, with just one base pair difference [14] , resulting in skipping of exon 7 in around 85-90% of SMN2 transcripts.
Without exon 7 the SMN2-derived protein is quickly degraded and, therefore, only low levels of functional SMN protein remain [15, 16] .
Several lines of evidence suggest that SMN is involved in the development and maintenance of motor neuron growth cones, axon, and neuromuscular junctions [17] [18] [19] [20] [21] mediated, at least in part, through its role in regulating ubiquitin homeostasis [22, 23] . In concert with other RNA binding proteins, SMN forms complexes both in the nucleus and the cytoplasm of neurons [24, 25] . As such, SMN protein has housekeeping roles in the assembly of ribonucleoprotein (RNP) complexes, including the U3 snoRNA [26] required for 18S ribosomal RNA biogenesis [27] and the small nuclear RNP (snRNP) required for processing of histone pre-mRNAs [28] . In addition, SMN localises to dendrites, synapses and axons in 4 vivo and in vitro [23, 29, 30] where it is part of messenger RNP (mRNP) complexes with well-known roles in the transport of mRNA [31, 32] . These cellular processes are tightly linked to local translation, suggesting that SMN may play a pivotal role in its regulation.
Indeed, SMN has previously been shown to associate with polyribosomes both in vitro [33] and in the rat spinal cord [29] . Moreover, components of the translational machinery are mislocalized in SMN-depleted cells [34] and the localisation and translation of specific mRNAs is altered in primary neurons derived from mouse models of SMA [17, 35, 36 ].
However, a direct link between SMN and the regulation of translation in vivo has not yet been demonstrated.
In the current study, we used polysomal profiling to directly investigate the role of SMN in protein translation, in vitro and in vivo, in an established mouse model of severe SMA at both early and late-symptomatic stages. We show that SMN depletion leads to widespread perturbations in translation, including defects in the fraction of ribosomes on polysomes and in the recruitment of mRNAs to polysomes. These defects are cell-autonomous, directly associated with SMA disease progression, and dependent upon SMN protein levels.
Sequencing of mRNAs associated to polysomes led to the identification of specific RNAs differentially translated in SMA. Functional annotation analysis of mRNAs with reduced translation efficiency revealed an enrichment for ribosomal components and proteins involved in translation; consistently, we observed a reduced number of axonal ribosomes in SMA motor neurons. Our findings, therefore, identify a key role for SMN in regulating translation and ribosome biology in vivo.
Results
Polysomal profiling reveals translational defects in in SMA
To test the hypothesis that low levels of SMN lead to defects in translation, we initially performed polysomal profiling on a set of tissues (brain, spinal cord, kidney and liver) harvested from the severe 'Taiwanese' SMA mouse model [23, 37] at pre-, early-and latesymptomatic stages of disease. We did not include disease end-stage mice in these initial experiments, as the severity of the phenotype at this time-point can likely lead to secondary, non-specific changes. Polysomal profiling is a powerful way of gathering a large amount of information about the translational state of biological systems, both in vitro and in vivo [38] [39] [40] [41] . Under both physiological and diseased conditions, it is possible to determine, : 1) the fraction of ribosomes engaged on polysomes, revealing the overall level and efficiency of translation [38] ; 2) the protein co-sedimentation profile with ribosomes and polysomes [2, 42] , and 3) the transcriptome-wide analysis of RNAs associated with polysomes (i.e. the translatome, POL-Seq) by next generation sequencing (NGS) [43] (Fig. 1a) . Graphical representations of typical polysome profiles generated by this approach are shown in The cytoplasmic localization of SMN, alongside its known role in mRNA transport along the axon and its potential association with both ribosomal proteins [44] and polysomes [29, 33] , prompted us to confirm its association with polysomes in vivo. To do that, we determined the co-sedimentation profiles of SMN in control and SMA brains and spinal cords by immunoblotting ( Fig. 1d and e) . The ribosomal proteins RPS6 and RPL26 were used as markers of the 40S and 60S subunits of the ribosome, respectively. We observed cosedimentation of SMN with the ribosomal subunits, the monosomes (80S) and polysomes in both brain (Fig. 1d) and spinal cord (Fig. 1e) from control mice. Co-sedimentation profiles generated from SMA mice demonstrated that, as expected, SMN protein abundance was strongly reduced and SMN co-sedimentation with polysomes was lost ( Fig. 1d and e) . To further demonstrate the association of SMN with polysomes, we treated the lysates with EDTA, to dissociate ribosomes into the small and large subunits of the ribosome. As expected, under these conditions, the sedimentation profile of SMN moved towards lighter 6 fractions (Supplementary Figure 1) . To exclude the association of SMN with hnRNPs and to further demonstrate the robust association of SMN with polysomes, we compared the cosedimentation profile of hnRNP A1 to that of SMN under control and EDTA conditions, and found no co-sedimentation of hnRNP A1 with SMN (Supplementary Figure 1) . Thus, SMN protein co-sediments with the translational machinery in vivo.
When comparing polysomal profiles from late symptomatic SMA and age-matched control tissue (Fig. 1b and c 
Translational impairment correlates with SMA disease progression
One major challenge in studying neurodegenerative diseases such as SMA is to distinguish true pathogenic changes, occurring early in pathogenesis, from downstream cellular phenotypes that represent later-stage consequences of the disease [47] . We therefore wanted to establish whether the translational defects we observed at late symptomatic stages were also an early hallmark of the disease. To this end, we calculated the fraction of ribosomes on polysomes (FRP) at pre-and early-symptomatic stage of the disease (Fig.2a and b) . Although no significant changes were apparent at pre-symptomatic stages, we identified a significant decrease in FRP at early-symptomatic stages in SMA brain, indicating that translation can be affected early in the disease process ( Fig. 2a; We next correlated body weight and righting time with the corresponding fraction of ribosomes on polysomes obtained from each individual mouse ( Fig. 2c and d) . Control and pre-symptomatic SMA mice showed a robust co-occurrence of high body weight and short righting time with a high FRP in brain (Fig. 2c) and spinal cord (Fig. 2d) . In contrast, results obtained from both early-and late symptomatic SMA mice were clearly distinct (Supplementary Figure 4) , and a progressive worsening of disease symptoms accompanied Having shown that the fraction of ribosomes on polysomes was decreased in SMA, and that translational impairment correlates with disease severity, we next wanted to establish whether these changes were directly dependent upon SMN protein levels. To assess this, we investigated the translational activity by determining the FRP in SMA mice that had been treated with an established ASO that leads to restoration of SMN levels [49, 50] . SMA mice were treated with a single intravenous injection of a 25-mer morpholino ASO (PMO25) that targets the SMN2 intron 7 splicing silencer N1. Following treatment, SMN2 exon 7 inclusion in the central nervous system (CNS) increased over two-fold [50] . Exon 7 inclusion leads to increased SMN protein levels (Supplementary Figure 5) and robust rescue of symptoms compared with non-treated SMA mice, as illustrated by increased body weights and decreased righting times (Supplementary Figure 6) , as well as increased survival [50] . We performed polysomal profiling after ASO treatment (Fig. 3a) and determined the FRP by analysing polysomal profiles from brain and spinal cord of control, SMA and ASO-treated SMA mice (Fig. 3b and Fig. 3c) . Loss of SMN from polysomes in late symptomatic SMA mice was associated with a significantly decreased FRP in brain and spinal cord compared to 8 littermate controls (Fig. 3c, brain Subsequent correlation of body weight and righting time with FRP confirmed the robust rescue as ASO-treated mice were indistinguishable from control mice (Fig. 3d and   Supplementary Figure 7) . Taken together, these results demonstrate that restoring SMN expression to normal levels rescues impairments in translation. Thus, translational defects observed in SMA are reversible and depend on SMN expression.
Translational impairment is most pronounced in primary affected brain regions and cell types in vivo and in vitro
The findings described above demonstrate that defects in ribosomal engagement on polysomes are a pronounced feature of SMA pathogenesis. However, these translational defects had only been observed at the level of whole tissues (e.g. spinal cord or brain) whilst pathological changes occurring in SMA are known to be restricted to specific anatomical regions and cell populations (e.g. motor neurons) within the brain and spinal cord [23] . We therefore wanted to investigate whether translational changes were more pronounced in particularly affected brain regions from SMA mice. First, we dissected three brain regions from control and late-symptomatic SMA mice and analysed them by determining the FRP by polysome profiling (Fig. 4a) . In line with previously observed pathological changes [51], we found significant defects in the cortex and hippocampus (both regions known to be affected in mice modelling severe SMA), while no changes were detected in the cerebellum (a region largely unaffected in SMA mice).
To determine whether the decrease in FRP was both cell autonomous and dependent on SMN loss, we next developed motor-neuron like cell lines (NSC-34) expressing SMN at different levels using CRISPR/Cas9 technology (see Supplementary Methods). We isolated and expanded two clones expressing 20% and 0% SMN, respectively (Supplementary Figure 9) , indicating that this assay provides a specific signal when used on primary motor neurons. When applying AHA metabolic labelling to primary SMA-derived motor and hippocampal neuron cultures, we observed a marked decrease in fluorescence intensity compared to primary cultures derived from control embryos ( Fig. 4b and fig. 4c ).
Quantification of this finding across 3 independent primary motor neuron preparations revealed a 37% decrease in fluorescence intensity when comparing SMA to control motor neurons (Fig. 4d) . Comparable quantification in primary hippocampal neurons indicated a more modest decrease in de novo protein synthesis of 21% (Fig. 4e) . These results confirm that the decreases in FRP previously observed at the level of whole tissues are compatible with defects occurring at the level of individual neurons, with the most robust defects in translational observed in the primary affected cell type in SMA, the motor neuron.
Taken together, the findings that de novo protein synthesis is impaired at the level of individual neurons and that FRP decrease is both brain region specific and correlates with SMN levels, suggest that the translational deficit is acell-autonomous event that depends specifically on the loss of SMN expression.
POL-Seq analysis reveals genome-wide impairment of translation efficiencies in early-and late-symptomatic SMA mice
Having identified robust translational defects in tissues, cell lines and individual primary motor neurons, we next went on to establish the consequences of these defects in the recruitment of mRNAs onto polysomes in SMA. We employed next generation sequencing (NGS) to identify and quantify, in parallel, the total cytoplasmic RNA (RNA-Seq) and the RNAs associated with polysomes (POL-Seq). This approach enables the simultaneous identification of variations in RNA populations at both translatome (RNAs engaged with polysomes) and transcriptome (steady state cytoplasmic RNAs) levels.
We extracted both total cytoplasmic and polysomal RNAs from pooled sucrose fractions from control, early-and late-symptomatic SMA mice, as illustrated in Fig. 5a . As these experiments represent the first application of translatome profiling to SMA tissues during disease progression, we included the complete POL-Seq and RNA-Seq datasets in a fully annotated, searchable and filterable format (Additional File 3). Among the most up and down-regulated transcripts in SMA (Fig. 5b) , we chose a set of nine differentially expressed genes that could be reliably detected using qPCR at both early and late symptomatic stages for subsequent validation. We confirmed the reproducibility of the NGS data by qPCR (Supplementary Figure 10) , finding a high concordance between the two techniques at both stages (r 2 =0.77 for early symptomatic stage, r 2 =0.99 for late symptomatic stage).
To understand if the variations in mRNA we previously identified at early-and latesymptomatic stages were also hallmarks of pre-symptomatic stages of the disease, we determined an expression time-course for the same transcripts that were selected for qPCR validation (Fig. 5c) . This showed that, although most transcripts were unchanged at the presymptomatic stage, several transcripts were differentially expressed, indicating some early pathogenic changes. Next, as our initial NGS and validation experiments were carried out on RNA isolated from brain tissue, we went on to determine the expression levels of our validation panel of transcripts in spinal cord. Importantly, the majority of changes observed at both early and late-symptomatic stages could be detected not only in brain but also in spinal cord (Fig. 5d) . These findings suggest that the changes captured at symptomatic stages are bona-fide features of subtle defects occurring at early stages of disease progression in disease-affected tissues.
Importantly, these changes were reversible, as ASO treatment (see Fig. 3 ) normalised the expression at both transcriptional and translational levels (Fig. 5e) . To confirm that at least some of the changes identified in SMA at the polysomal level resulted in corresponding changes at the protein level, we measured levels of UBA6 in SMA mice. This transcript was down-regulated only at the translational level and showed a concomitant decrease in protein abundance, confirming the accuracy of our translation measurements (Fig. 5f) .
Next, to establish the global effect of impaired translation in SMA on individual RNA transcripts, we used the ratio between POL-Seq and RNA-Seq abundances to determine and compare the translation efficiencies (TE) of individual RNA transcripts in control and SMA tissues [54, 55] . This analysis allowed us to highlight transcripts that have a significantly altered TE between control and SMA at the transcriptome-wide level, both at early and late symptomatic stages of the disease (Fig. 6a) . We found that 470 and 442 transcripts were significantly altered in TE at the early and late symptomatic stages, respectively (Supplementary Data 2). Interestingly, most RNAs with altered TE were protein coding, but a substantial proportion of these RNAs were noncoding (long noncoding and antisense being the most represented categories, Fig. 6b ).
To better understand the molecular processes associated with these mRNAs, we performed Gene Ontology and pathway enrichment analyses specifically on transcripts that had changed TE values in SMA at either early or late stages of the disease (Additional File 4). Focusing our attention initially on transcripts with reduced levels of TE at early stages of disease, we found strong enrichments in two major cellular processes: nucleosome/chromatin and ribosome/translation. Interestingly, however, when examining transcripts with decreased TE, only the ribosome/translation category was robustly conserved between early and late stages of disease (Fig. 6c) . This suggests that defects in ribosome/translation pathways are an early event in SMA pathogenesis, persisting into late stages of the disease.
Defects in ribosome biology are hallmarks of SMA
After having established that genome-wide changes in TE underlie defects in ribosome/translation occurring during SMA pathogenesis, we identified transcripts with a significant reduction of TE and associated with the Reactome pathway "translation" (Fig. 6c) ,
revealing a large majority of ribosomal proteins, with factors involved in translation initiation and elongation (Fig. 7a) . To validate these findings, we quantified individual transcript levels for fourteen ribosomal genes and one translation factor by qPCR (Fig. 7b) .
These experiments confirmed that the expression levels of numerous individual genes involved in ribosome biogenesis [56] [57] [58] are affected in SMA, both at early-and latesymptomatic stages of disease and suggest that defects in ribosome abundance could underlie, at least in part, the translational defects that occur in SMA.
To prove this hypothesis and investigate whether the down-regulation of translationrelated transcripts was reflected by defects in ribosome abundance in motor neurons in vivo,
we performed ultrastructural analyses of ribosomes in banked samples of intercostal nerves isolated from symptomatic severe SMA mice and littermate controls, where neuropathological changes have previously been established [59] . As expected [60] , transmission electron microscopy revealed prominent axonal ribosomes in both control and SMA mice (Fig. 7c) . Quantitative analyses of axonal ribosomal density revealed a 27% decrease in the number of axonal ribosomes in intercostal nerves from SMA mice versus controls (Fig. 7d) . Thus, defects in translational pathways and ribosome biology that occur at 12 the molecular level in SMA are accompanied by structural defects in the ribosomal machinery.
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Discussion
Increasing evidence suggests a role for translational defects in the pathogenesis of a variety of neurodegenerative diseases. Ribosomal defects have been documented in conditions such as Alzheimer's disease, Huntington's disease, Parkinson's disease and frontotemporal dementia [5] [6] [7] . Furthermore, translation factors are mutated in Vanishing White Matter disease [61] , in epilepsy and in mental retardation [62] [63] [64] . Here we found that the SMN protein, whose loss causes SMA, is an important mediator of translation biology in the nervous system. Depletion of SMN in SMA resulted in a range of translational defects in affected tissues and cells. We employed a range of methods to specify the role of SMN in regulating translation in vitro and in vivo, using next generation sequencing approaches to determine transcriptome-wide changes that occur in the translatome in SMA pathogenesis.
The identification of a transcriptome-wide set of differentially translated genes in SMA provided an important advancement in our understanding of motor neuron disease biology, as it allowed the determination of specific changes that occur downstream of translational defects. We also established that SMN depletion leads to an early and robust impairment of translation-related transcripts in SMA, and consequent defects in ribosomal biology that could provide a promising biomarker candidate for SMN-targeted clinical trials for SMA. In addition, we demonstrated that translational defects are cell-autonomous and can be rescued by therapies restoring SMN protein levels.
Our findings provide the first in vivo evidence to support the hypothesized physiological role of SMN in the localization of the translation machinery and translation of specific transcripts proposed previously in in vitro studies [33] [34] [35] [36] . In accordance with our findings, SMN has been shown to localize to the nucleolus, where it interacts with U3 snoRNA, which is involved in the processing of ribosomal RNA (rRNA) [26] . Similarly, the characterization of the SMN interactome identified likely interactions between the SMN complex and numerous ribosomal proteins, as well as the translation elongation factor eEF1A1 [44] .
Moreover, another recent study identified a number of ribosomal proteins amongst the most prominently down-regulated transcripts and proteins at vulnerable neuromuscular junctions in SMA [65] .
One longstanding issue in several neurodegenerative diseases is the lack of a robust explanation for the cell-type specificity in the presence of defects of ubiquitously expressed proteins. Indeed, this is also a hallmark of the SMA disease following ubiquitous depletion of SMN protein [66] . Although spinal motor neurons are the most prominently affected cell type, numerous other cell-types and tissues can also be affected in SMA, albeit to a lesser extent, both in patients and a range of animal models of the disease [67] [68] [69] . The translational defects we report here were notably most pronounced in spinal cord and brain, with more modest defects observed in the kidneys and no observable defects in the liver. These findings support a threshold model for the requirement of SMN, where different tissues and cell-types require different minimal levels of SMN [70] . Our data would therefore suggest that defects in translation and ribosome biology are major downstream mediators of the effects of SMN on different tissues in SMA. In line with this model, we found that when comparing different CNS tissues (cortex, hippocampus and cerebellum) and cell-types (primary hippocampal and motor neurons), the tissues and cell-types known to be most affected in SMA showed the biggest defects in translational activity.
Taken together with findings from other neurodegenerative conditions, we might hypothesize that translation may represent a common defective feature across a variety of motor neuron diseases mediated by mutations in proteins involved in RNA metabolism.
Indeed, several recent studies of the adult-onset motor neuron disease amyotrophic lateral sclerosis (ALS) have pointed towards a role for translational defects in motor neuron degeneration. For example, the main pathological protein in ALS, TDP43, has been shown to regulate the translation of specific transcripts [71] . Also, ALS-associated protein aggregates have been shown to affect the function of proteins that play an important role in regulating translation, such as FMRP [72, 73] . Moreover, EM analysis of patient nerves indicated the mislocalisation of ribosomes in ALS patients [74] . It is interesting to note that many proteins that have been implicated in regulating translation and have been associated to neurodegenerative diseases are known to interact as part of bigger RNA-protein complexes [73, [75] [76] [77] . This complicates the process of unravelling causative from secondary changes in disease, as likely functional redundancy in these complexes makes it challenging to detail true pathogenic changes. By showing that defects in translation are a prominent feature of SMA, we provide new insights into these challenging questions and wonder if defects in ribosome turnover, that is known to be tissue-specific, may play a role in producing tissuespecific defects in neurodegenerative diseases caused by ubiquitously expressed proteins involved in RNA metabolism.
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Methods
Animal models and ASO treatment
The 'Taiwanese' mouse model of severe SMA was used in this study [37, 78, 79] . All mice were on a congenic FVB background, with colonies at the University of Edinburgh and UCL established from breeding pairs originally purchased from Jackson Labs. 'Taiwanese' SMA mice (Smn-/-; SMN2tg/0) carry two copies of SMN2 on one allele and are on a null murine Smn background. Phenotypically normal heterozygous (Smn-/+;SMN2tg/0) littermates were used as controls. Mice were maintained following a breeding strategy previously described [78] . For EM experiments, tissue that had previously been banked from a 'severe' SMA mouse colony was used, as described previously [80] . Litters were retrospectively genotyped using standard PCR protocols. All mice were housed within the animal care facilities in Edinburgh and London under standard SPF conditions. All animal procedures and breeding were performed in accordance with University of Edinburgh and UCL institutional guidelines and under appropriate project and personal licenses granted by the UK Home Office.
Antisense oligonucleotide treatment was performed as previously described, using PMO25 that targets SMN2 intron 7 splicing silencer N1 [50] . It is known that the disease progression of transgenic mice can vary between laboratories, even when the same transgenic model is used [81] . For clarity, throughout the paper we refer to the time points at which tissue was collected as pre-, early and late symptomatic throughout the paper. In Edinburgh, presymptomatic was P3, early symptomatic was P5 and late symptomatic was P7 (for figures [1] [2] [3] [4] [5] and S1-S5). The tissue obtained from UCL (figure 6 and S7-S9) was from late symptomatic (P10) mice that were phenotypically similar to P7 mice maintained in Edinburgh.
Motor performance test
All mice used in the study were weighed daily. Motor performance was recorded using the righting reflex test, which is a common assay for neuromuscular function in neonatal mice [23, 82] and involves placing the mouse on its back on a flat surface and recording the time it takes to turn over onto its paws. If a mouse took longer than 30 seconds to right itself then the test was terminated. The righting test was performed in triplicate for each mouse and an average righting time was calculated.
Tissue isolation
Neonatal mice were euthanized by overdose of anaesthetic, before decapitation to allow the brain to be removed. Spinal cord dissection was performed by first removing the spinal column and then using a needle and syringe to flush out the spinal cord with phosphate buffered saline (PBS) [52] . This technique leads to the isolation of intact spinal cord, which is important for sample preparation for polysome analysis. Peripheral tissues (kidney, liver)
were subsequently dissected. Following isolation, all tissues were immediately snap-frozen on dry ice and then transferred to -80 °C for storage.
Primary neuronal cultures
Primary motor neurons and hippocampal neurons were cultured as described previously [73, 83] . Taiwanese mice breeding pairs were set up as described above as timed matings to obtain heterozygous (Smn+/-; SMN2tg/0) and Smn null (Smn-/-; SMN2tg/0) embryos. At E13
(motor neurons) and E15 (hippocampal neurons), timed pregnant females were euthanized by cervical dislocation. Each embryo was processed individually and separately as genotyping was done retrospectively. For motor neurons, the ventral part of the spinal cord was dissected from each embryo, trypsinized using 0.05 % trypsin for 15 minutes at 37°C, treated with DNAsel (Sigma) and dissociated into a single cell suspension by trituration with a pipette.
The cell suspension was separated using a 6.2% Optiprep gradient (Sigma) and centrifugation at 680 x g for 15 minutes. The motor neuron-containing fraction was pelleted and plated onto coverslips coated with poly-D,L-ornithine and laminin at a density of 10,000 cells per well in a 24 well plate. For mixed cultures of primary hippocampal neurons, the hippocampus was dissected and incubated in 0.25% trypsin for 15 min at 37°C after which the tissue was dissociated into single cells using fire-polished glass pipettes in culture medium (neurobasal medium supplemented with B27, glutamax, HEPES and penicillin/streptomycin).
Hippocampal neurons were plated onto poly-D-lysine and laminin coated coverslips at a density of 20,000 cells per well in a 24-well plate. All primary cultures were grown in an incubator at 37°C and 5% CO2.
Labeling of newly synthesized proteins in primary neurons
Novel protein synthesis in heterozygous control and SMA primary neurons was quantified using metabolic labeling with L-azidohomoalanine (AHA) using the Click-IT® AHA kit (ThermoFisher Scientific) according to the manufacturer's recommendations. Briefly, after 7 days in culture, cells were washed with prewarmed PBS and the medium was replaced with methionine-free medium, supplemented with B27, Glutamax and l-azidohomoalanine and incubated for 30 minutes. The cells were subsequently fixed in prewarmed 4% PFA and permeabilized in 0.5% triton-X100 in PBS. A chemoselective ligation reaction between an azide and an alkyne allowed for subsequent labelling of newly synthesized proteins using Alexa Fluor 488. Cells were also labelled with nuclear marker DAPI. Primary neurons were imaged on a Zeiss LSM710 confocal microscope, where all healthy and morphologically normal neurons on a coverslip were imaged for subsequent analysis. The same confocal settings were used within each experiment for both SMA and control neurons. Images were subsequently analyzed in FIJI; the cell body was manually delineated and the mean fluorescence intensity was measured for each neuron. All analyses were performed with the operator blind to the genotype or treatment. The average fluorescence intensity was then calculated for heterozygous control and SMA motor neurons. As a control, the protein synthesis inhibitor anisomycin was used. Neurons were pre-treated with 40 µM anisomycin for 30 minutes, after which the medium was replaced with methionine-free medium as above, with the addition of 40 µM anisomycin. Cells were subsequently processed as described above.
Polysome profiling
Cytoplasmic lysates from frozen mouse tissues were prepared as described previously [84] . Briefly, brains and spinal cords were pulverized in a pestle and mortar cooled by liquid nitrogen and the obtained powders were lysed in 0.8 mL of lysis buffer (10 mM Tris-HCl at pH 7.5, 10 mM NaCl, 10 mM MgCl2, 1% Triton-X100, 1% Na-deoxycholate, 600 U/ml RiboLock Rnase Inhibitor (Thermo Scientific), 1 mM DTT, 0.2 mg/ml cycloheximide, 5 U/ml Dnase I (Thermo Scientific)) by vigorous pipetting. Two consecutive centrifuges of 1 and 5 minutes respectively at 18,000 g at 4°C were performed to first remove cellular debris and then nuclei and mitochondria. The supernatants were immediately loaded on a linear sucrose gradient (15-50% sucrose [m/v], in 100 mM NaCl, 10 mM MgCl2, 10 mM Tris/HCl pH 7.5) and ultracentrifuged in a SW41Ti rotor (Beckman) for 1 h 40 min at 180,000 g at 4°C in a Beckman Optima™ LE-80K Ultracentrifuge. After ultracentrifugation, gradients were fractionated in 1 ml volume fractions with continuous monitoring absorbance at 254 nm using an ISCO UA-6 UV detector. Cytoplasmic lysates from cells were prepared as already described [40] . For EDTA treatment, the lysates were supplemented with 8 mM EDTA and left for 10 minutes on ice before being loaded on the gradients.
Protein extraction from polysomal fractions and Western Blotting
Proteins were extracted from each sucrose fraction of the profile using the %Pn = 100 * Dpn / sum Dpni, where Pn is the percentage of the protein in the fraction n; Dpn is the density of the protein in the fraction n and N is the total number of fractions. Western blots for NGS validation experiments were analysed using ImageStudio (LICOR).
Analysis of the fraction of ribosomes on polysomes
The fraction of ribosomes on polysomes (FRP) was calculated from polysomal profiles as the ratio between the area under the curve of polysomes and the area under the curve of polysomes plus the area of the 80S peak. FRP was calculated for at least three different polysomal profiles (min 3 -max 9) for each tissue (spinal cord or brain), physiological condition (heterozygous control or SMA) and disease stage (pre-, early or late symptomatic). To bypass the problem of unclear discrimination of the 80S and polysomal peaks due to the sensitivity of absorbance along the sucrose gradient (for example, when the amount of tissue was limited), we first applied a blank profile subtraction. For each polysomal profiling run, 800 μL of lysis buffer was loaded on a gradient. The lysis buffer profile obtained was then subtracted from each tissue profile, which improved the final polysomal chromatogram and allowed for a more precise calculation of the FRP.
Isolation of total and polysomal RNA and cDNA library preparation
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RNA was extracted from control and SMA brains (at pre, early and late symptomatic stage), from ASO brains (at late symptomatic stage) and from control and SMA spinal cords (at late symptomatic stage). Profile fractions (total RNA) or polysomal fractions only (polysomal RNA) were pooled together. The fractions were first digested with proteinase K (100 mg/mL, Euroclone) for 90 minutes at 37°C and then RNA was extracted with acidphenol:chloroform:isoamylalcohol, pH 4.5 (Sigma Aldrich) and isopropanol precipitation.
cDNA libraries were produced starting from 500 ng of total or polysomal RNA (early and late symptomatic stage) using the TruSeq® Stranded Total RNA (Illumina) kit according to manufacturer's instructions.
NGS data analysis
RNA-Seq and POL-Seq sequencing was performed with an Illumina HiSeq 2000 (Mus musculus, GPL13112). Fastq files were checked for quality control with FastQC. 100 bp reads generated from each sample were aligned to the mouse genome (GRCm38.p4) with
Tophat (version 2.0.14), using the Gencode M6 transcript annotation as transcriptome guide.
All programs were used with default settings unless otherwise specified. Mapped reads (ranging from 84% to 92% of total reads, Supplementary 
Electron microscopy
Tissue was prepared, processed and imaged using transmission electron microscopy as described previously [80] .
Statistical methods
For hierarchical clustering based on FRP, relative weight and relative righting time data were first rescaled in order for each variable to have the same mean and standard deviation. 
Additional files
Additional File 1: Supplementary Methods, Supplementary Figures 1-9 and Supplementary   Tables 1-2 Additional file 2: mice phenotypic and FRP data. 
